^
    1d
    MiRaDoR: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population (clinicaltrials.gov)
    P2, N=976, Recruiting, MedSIR | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Dec 2028 --> Jun 2028
    Trial completion date • Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint®
    |
    Verzenio (abemaciclib) • Itovebi (inavolisib) • giredestrant (RG6171)
    1d
    Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    carboplatin • albumin-bound paclitaxel • Zolinza (vorinostat)
    1d
    Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer (clinicaltrials.gov)
    P=N/A, N=350, Suspended, City of Hope Medical Center | Initiation date: Jan 2026 --> May 2026
    Trial initiation date • Minimal residual disease • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    2d
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2d
    TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Baylor College of Medicine | Trial completion date: Sep 2034 --> Jan 2044 | Trial primary completion date: Sep 2028 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    2d
    Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study. (PubMed, Breast Cancer Res)
    Chidamide combined with fulvestrant showed encouraging antitumor activity and tolerable toxicity in pts with HR + /HER2- advanced breast cancer that had progressed after previous endocrine therapy. Trial registration ChiCTR2100044282, registered on March 14th 2021.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • Epidaza (chidamide)
    2d
    A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=240, Recruiting, Stemline Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    Orserdu (elacestrant) • MEN2312
    3d
    Characteristic Hepatic Atrophy in Abemaciclib-Induced Liver Injury: A Comparative Review of Three Cases. (PubMed, Hepatol Res)
    This report is the first highlighting the imaging characteristics of rapid-onset hepatic atrophy associated with abemaciclib-induced liver injury. These findings may provide useful insights for distinguishing abemaciclib-induced liver injury from other etiologies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole
    3d
    NATALEE: A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (clinicaltrials.gov)
    P3, N=5101, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2026 --> May 2030 | Trial primary completion date: May 2026 --> May 2030
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict®
    |
    Kisqali (ribociclib)
    3d
    HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=40 --> 7
    Enrollment closed • Enrollment change
    3d
    MRT-2359-001: Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=174, Active, not recruiting, Monte Rosa Therapeutics, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    HR positive • HER-2 negative • MYCN amplification
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359